Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02296242
Title Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors BioMed Valley Discoveries, Inc
Indications

acute myeloid leukemia

bone marrow cancer

Therapies

Ulixertinib

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
UCLA Medical Center Los Angeles California 90024 United States Details
Winship Cancer Institute of Emory University Atlanta Georgia 30322 United States Details
Roswell Park Cancer Institute Buffalo New York 14263 United States Details
Perelman Center for Advanced Medicine Philadelphia Pennsylvania 19104 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field